The global nuclear medicine/radiopharmaceuticals market expected to be US$ 3,982.11 Mn in 2018 and is predicted to grow at a CAGR of 6.2% during the forecast period 2019 - 2027, to reach US$ 6,683.99 Mn by 2027. Europe is the second largest geographic market and is expected to be the second most significant revenue contributor throughout the forecast period. The region has witnessed several technological advancements in the field of healthcare by the incorporation of advanced nuclear medicines in order to increase the efficiency of imaging processes in the region. The growth is driven by factors such as the rising prevalence of neurologic disorders such as, Alzheimer’s and others along as well as the rising focus by market players in the European countries.